Jamie Dananberg
Chief Tech/Sci/R&D Officer at ANNEXON, INC.
Net worth: 371 606 $ as of 2024-03-30
Profile
Jamie Dananberg is currently the Chief Medical Officer at Annexon, Inc. and a Trustee at Keck Graduate Institute of Applied Life Sciences.
Previously, he worked as the VP-Translational Medicine & Tailored Therapeutics at Eli Lilly & Co. from 2000 to 2012, as the Executive Vice President at Takeda Pharmaceutical Co., Ltd.
from 2012 to 2015, and as the Chief Medical Officer at Unity Biotechnology, Inc. from 2016 to 2023.
He received his undergraduate and doctorate degrees from Tufts University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ANNEXON, INC.
0.04% | 2024-02-15 | 39,000 ( 0.04% ) | 279 630 $ | 2024-03-30 |
| 2023-04-23 | 56,083 ( 0.33% ) | 91 976 $ | 2024-03-30 |
Jamie Dananberg active positions
| Companies | Position | Start |
|---|---|---|
| ANNEXON, INC. | Chief Tech/Sci/R&D Officer | 2023-07-26 |
| Keck Graduate Institute of Applied Life Sciences | Director/Board Member | - |
Former positions of Jamie Dananberg
| Companies | Position | End |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Chief Tech/Sci/R&D Officer | 2023-04-29 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 2015-09-30 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 2012-08-31 |
Training of Jamie Dananberg
| Tufts University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ANNEXON, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
- Stock Market
- Insiders
- Jamie Dananberg
